Richmond, Australia

Shaun Patrick Gaynor

USPTO Granted Patents = 2 



Average Co-Inventor Count = 9.0

ph-index = 1

Forward Citations = 5(Granted Patents)


Company Filing History:


Years Active: 2014-2015

Loading Chart...
Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Shaun Patrick Gaynor: Innovator in Thiopyrimidine-based Compounds

Introduction

Shaun Patrick Gaynor is a notable inventor based in Richmond, Australia. He has made significant contributions to the field of medicinal chemistry, particularly through his work on thiopyrimidine-based compounds. With a total of 2 patents, his innovations focus on developing inhibitors for protein kinases, which play a crucial role in various diseases.

Latest Patents

Gaynor's latest patents include the invention of thiopyrimidine-based compounds that serve as inhibitors of protein kinases, specifically targeting JAK kinases. These compounds are selective for JAK1, JAK2, or JAK3 kinases, and combinations thereof, such as JAK1 and JAK2. The kinase inhibitors developed by Gaynor can be utilized in the treatment of several kinase-associated diseases, including immunological and inflammatory diseases, hyperproliferative diseases like cancer, viral diseases, metabolic diseases, and vascular diseases.

Career Highlights

Throughout his career, Shaun Patrick Gaynor has worked with various organizations, including Ym Biosciences Australia Pty Ltd. His expertise in the field has allowed him to contribute to significant advancements in therapeutic solutions.

Collaborations

Gaynor has collaborated with notable professionals in his field, including David Gerard Bourke and Xianyong Bu. These collaborations have further enhanced his research and development efforts.

Conclusion

Shaun Patrick Gaynor is a distinguished inventor whose work on thiopyrimidine-based compounds has the potential to impact the treatment of various diseases significantly. His contributions to medicinal chemistry continue to pave the way for innovative therapeutic solutions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…